Thus, increasing the NAD+/NADH ratio by administering nicotinamide mononucleotide (NMN), another NAD+ precursor, has been shown to have a protumorigenic effect in K-Ras-driven pancreatic cancer (Nacarelli et al., 2019), unveiling the complexity of these therapeutic approaches. This evidence concerns the gene KRAS and familial pancreatic carcinoma.